More About Jivi®

Click to expand section.

Jivi® is a PEGylated rFVIII with an extended half-life* of

  • PEG, polyethylene glycol; rFVIII, recombinant Factor VIII.
  • Half-life is defined as the time it takes for the amount of a drug in the blood to decrease by one half.6
  • With a single, 60 IU/kg dose (IU, international units; kg, kilograms).1

Jivi® is indicated for previously treated adolescents (12 years of age and older) and adults with hemophilia A

of prophylaxis patients from the main clinical study opted into the long-term extension study1†
  • As of January 2015 interim analysis.7
  • 107 of 110 prophylaxis patients from the main study opted into the extension study.1